Skip to main content

Table 1 Patient characteristics measured at the start of each medication treatment episode

From: Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study

Baseline covariates (%)

ABA

ADA

ETA

INF

LEF

MTX

RIT

SSZ-HCQ

Total

( N  =  27 )

( N  =  116 )

( N  =  113 )

( N  =  29 )

( N  =  110 )

( N  =  183 )

( N  =  24 )

( N  =  357 )

( N  =  959 )

Unique patients

25

113

112

26

98

170

18

302

566

Mean age, years (SD)

60.5 (8.2)

61.0 (9.9)

61.2 (9.7)

57.1 (9.4)

64.5 (11.0)

62.2 (10.6)

62.2 (7.7)

62.3 (10.5)

62.1 (10.3)

Male gender

25 (92.6)

106 (91.4)

108 (95.6)

23 (79.3)

101 (91.8)

167 (91.3)

23 (95.8)

327 (91.6)

880 (91.8)

Medication use six months prior start of treatment episode

    

MTX/LEF

18 (66.7)

71 (61.2)

69 (61.1)

20 (69.0)

51 (46.4)

17 (9.3)

12 (50)

145 (40.6)

403 (42.0)

HCQ/SSZ

4 (14.8)

18 (15.5)

19 (16.8)

4 (13.8)

21 (19.1)

68 (37.2)

3 (12.5)

45 (12.6)

182 (19.0)

Oral glucocorticoids

9 (33.3)

43 (37.1)

50 (44.3)

8 (27.6)

39 (35.5)

68 (37.2)

13 (54.2)

117 (32.8)

347 (36.2)

HBV antivirals1

1 (3.7)

5 (4.3)

2 (1.8)

0 (0)

0 (0)

3 (1.6)

0 (0)

12 (3.4)

23 (2.4)

Comorbidities2

       

Hepatitis C

5 (18.5)

18 (15.5)

23 (20.4)

7 (24.1)

6 (5.5)

11 (6.1)

6 (25.0)

69 (19.3)

145 (15.1)

COPD

4 (14.8)

13 (11.2)

19 (16.8)

8 (27.6)

20 (18.2)

5 (19.1)

7 (29.2)

65 (18.2)

171 (17.8)

Hypertension

15 (55.6)

65 (56.0)

65 (57.5)

14 (48.3)

76 (69.1)

112 (61.2)

14 (58.3)

236 (66.1)

597 (62.3)

Diabetes mellitus

4 (14.8)

22 (19.0)

19 (16.8)

2 (6.9)

19 (17.3)

50 (27.3)

4 (16.7)

90 (25.2)

210 (21.9)

Solid cancer

2 (7.4)

6 (5.2)

5 (4.4)

2 (6.9)

17 (15.5)

21 (11.5)

2 (8.3)

31 (8.7)

86 (9.0)

  1. 1HBV antivirals - lamivudine, entecavir, tenofovir, telbivudine, adefovir, emtricitabine, emtricitabine/tenofovir; 2defined by International Classification of Diseases, Ninth Revision (ICD-9) codes and measured 12 months prior to the index date. ABA, abatacept; ADA, adalimumab; ETA, etanercept; INF, infliximab; LEF, leflunomide; MTX, methotrexate; RIT, rituximab; SSZ-HCQ, sulfasalazine/hydroxychloroquine; SD, standard deviation; HBV, hepatitis B virus; COPD, chronic obstructive pulmonary disease.